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SUMMARY

Author Manuscript

The mechanisms by which immune checkpoint blockade modulates tumor evolution during
therapy are unclear. We assessed genomic changes in tumors from 68 patients with advanced
melanoma, who progressed on ipilimumab or were ipilimumab-naive, before and after nivolumab
initiation (CA209-038 study). Tumors were analyzed by whole-exome, transcriptome, and/or Tcell receptor (TCR) sequencing. In responding patients, mutation and neoantigen load were
reduced from baseline, and analysis of intratumoral heterogeneity during therapy demonstrated
differential clonal evolution within tumors and putative selection against neoantigenic mutations
on-therapy. Transcriptome analyses before and during nivolumab therapy revealed increases in
distinct immune cell subsets, activation of specific transcriptional networks, and upregulation of
immune checkpoint genes that were more pronounced in patients with response. Temporal
changes in intratumoral TCR repertoire revealed expansion of T-cell clones in the setting of
neoantigen loss. Comprehensive genomic profiling data in this study provide insight into
nivolumab mechanism of action.

Author Manuscript

eTOC
Mutation burden decreases with successful checkpoint blockade therapy in patients with
melanoma, suggesting that selection against protective mutant neoepitopes may be a critical
mechanism of action of Nivolumab

Author Manuscript
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INTRODUCTION

Author Manuscript

Immune checkpoint inhibitors have demonstrated improved overall survival (OS) and
progression-free survival (PFS) in the treatment of many different tumor types (Brahmer et
al., 2015; Ferris et al., 2016; Hodi et al., 2016; Motzer et al., 2015; Robert et al., 2015). The
underlying genomic features of a tumor can contribute to its response to checkpoint
blockade, and increased tumor mutation load associates with survival benefit from both antiCTLA-4 and anti-PD-1 therapy in multiple malignancies (Hugo et al., 2016; Le et al., 2015;
Rizvi et al., 2015; Rosenberg et al., 2016; Snyder et al., 2014; Van Allen et al., 2015). High
tumor mutation load may increase the probability of generating immunogenic neoantigens,
which facilitate recognition of a tumor as foreign (Riaz et al., 2016a; Schumacher and
Schreiber, 2015). Thus, tumors with a high number of clonal neoantigens may be more
likely to elicit effective immune responses (McGranahan et al., 2016).

Author Manuscript

Features of the tumor microenvironment (TME) also associate with response to checkpoint
inhibitor therapy. Expression of PD-L1 in the TME associates with clinical response to antiPD-1/PD-L1 therapies in multiple tumor types (Herbst et al., 2014; Topalian et al., 2012).
Baseline levels of tumor-infiltrating CD8+ T cells correlate with the likelihood of response,
and may increase during therapy in responding but not progressing tumors (Topalian et al.,
2016; Tumeh et al., 2014). Further, the location of CD8+ T cells at the invasive margin of
tumors may indicate an effective immune response (Chen et al., 2016; Spranger et al., 2015;
Tumeh et al., 2014). The TME may limit extravasation of effector T cells into the tumor,
diminish T-cell expansion, or reduce the viability of tumor-infiltrating lymphocytes (TILs)
(Joyce and Fearon, 2015).
How checkpoint inhibitor-mediated immune activation modulates the mutational landscape
of the tumor and the TME remains poorly understood. To characterize genomic changes, we
performed comprehensive genomic analyses on melanoma samples pre- and post-nivolumab
(Nivo; anti-PD-1 agent) therapy.

RESULTS
Author Manuscript

Genomic Characteristics of Tumors before Nivo Treatment
Pre-therapy biopsies from 68 patients were assessed by whole-exome sequencing (WES) at
150× (mean depth: 168; range: 121–237) (Table S1). Thirty-five patients had previously
progressed on ipilimumab (Ipi) therapy (Ipi-P); 33 patients were Ipi-naive (Ipi-N) (Table
S2). In the patients with WES data, rates of response (RECIST v1.1-defined complete
response [CR] or partial response [PR]) to Nivo were comparable in Ipi-N (21%) and Ipi-P
(22%) patients. Median mutation load in the patient cohort was 183 mutations (range: 1–
7360; interquartile range: 44–433; Table S2,3) and did not differ significantly between Ipi-N
Cell. Author manuscript; available in PMC 2018 November 02.
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and Ipi-P patients (Figure 1A). Mutational subtypes of melanoma as defined by The Cancer
Genome Atlas (TCGA) (Cancer Genome Atlas Network, 2015) did not differ in response to
Nivo. There were more triple wild type (WT) patients in the Ipi-P cohort than the Ipi-N
cohort (57% versus 33%, p = 0.06; Fisher’s exact test; Figure 1A).
Tumor and Clonal Mutation Load Are Associated with OS and Response in Nivo-Treated
Ipi-N Patients

Author Manuscript

Tumor mutation load associated with OS in Ipi-N but not Ipi-P patients (Figures 1B and
S1A), and Ipi-P patients tended to have lower numbers of clonal mutations (p = 0.08; Figure
S1B). Stratification of patients by the number of clonal mutations improved the ability to
predict survival and response of Ipi-N but not Ipi-P patients (Figures 1B, S1C and S1D).
Mutation signatures may play a role in response to checkpoint blockade in NSCLC (Rizvi et
al., 2015); however, here, no relationship between the proportion of mutations due to any of
the known melanoma mutation signatures (e.g., UV or aging) (Alexandrov et al., 2013) and
response to therapy was observed (Figure 1A).

Author Manuscript

No single gene mutations were significantly associated with response or resistance to
therapy. SERPINB3/B4 gene mutations in melanoma samples associate with response to
anti-CTLA-4 therapy (Riaz et al., 2016b), and here, five of six patients with SERPINB3/B4
mutations had disease control (CR/PR or stable disease [SD]); however, this was not
statistically significant, likely due to small numbers (p = 0.21; Fisher’s exact test). One
patient with PR had a frame-shift alteration in B2M with corresponding loss of
heterozygosity, alterations previously associated with acquired resistance to anti-PD-1
therapy (Zaretsky et al., 2016). JAK1 and JAK2 mutations were not associated with
resistance in this cohort (Figure 1A). No recurrent copy-number alterations as determined by
TCGA associated with response; nor did copy-number alterations in interferon (IFN) genes
on chromosome 9p (Figures S1E and S1F). However, the frequency of global genomic
instability (Davoli et al., 2017) associated with OS in Ipi-P but not Ipi-N patients (Figure
S1G).
Evolution of Tumors during Nivo Treatment

Author Manuscript

To determine if Nivo therapy affects tumor mutation load and intratumor heterogeneity,
WES was performed on a subset (n = 41) of paired pre- and on-therapy biopsy samples
(Table S4). Significant differences between pre- and on-therapy biopsies correlated with
response (p = 5.87e–5; Mann–Whitney test for CR/PR versus progressive disease [PD])
(Figures 1C, S1H, and S1I). Among Ipi-N and Ipi-P responders, a reduction in mutation and
neoantigen load was observed 4 weeks after initiation of Nivo, perhaps consistent with
immunoediting (Tables S5A and S5B). To ensure that these observations were not solely due
to changes in tumor purity after therapy, further deep sequencing (300×) was performed on
responding tumors. In each case, many of the mutations seen in the pre-therapy samples
were still detectable in on-therapy samples (Figures S2A–S2C). The proportion of mutations
that remained detectable varied depending on response: the mean fraction of variants in ontherapy samples was 19% for CR/PR (range: 1%–99%), 82% for SD (range: 2%–140%) and
101% for PD (range: 33%–205%) (values greater than 100% indicate additional mutations
beyond those in pre-therapy samples were detected). Power calculations, assuming a global

Cell. Author manuscript; available in PMC 2018 November 02.
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five-fold decrease in the variant allele frequency on-therapy (see Methods), demonstrated
that the magnitude in change of mutation load could not be explained by changes in tumor
purity alone (Figures S2D–S2F). There were four cases of focal loss of CDKN2A that
appeared in on-therapy samples, all in patients with PD. In three of these patients,
chromosome 9p deletions also included the nearby IFN gene cluster.

Author Manuscript

Subsequently, we examined association of changes in the clonal compositions of paired preand on-therapy tumor samples with response. The fraction of tumor cells carrying a variant
(cancer cell fraction, CCF) in both pre- and on-therapy samples was estimated (see
Methods) (Roth et al., 2014). The temporally related changes that occurred in the clonal
composition of tumors differed between response groups. Patients with CR/PR had
markedly high frequencies of tumor clonal and subclonal variants that decreased in
prevalence after Nivo therapy and, in many cases, were not detected on-therapy (mutational
contraction; see Methods; Figure 2A). The relative frequencies of single nucleotide
variations (SNVs) undergoing mutational contraction were significantly less in patients with
PD than SD (p = 0.01). In addition, the relative frequencies of novel SNVs detectable ontherapy were significantly higher on a per-sample basis in patients with PD than SD (p =
0.02), consistent with presumed mutational expansion and/or genetic drift (Figure 2B). Net
genomic changes (defined as the difference of variants representing mutational contraction
and mutational persistence [see Methods]) per sample strongly associated with response and
OS, and this metric was superior to the temporal change in mutation load in predicting
response (Figure 2C). Tumors from patients with SD were identified as an intermediate
molecular phenotype between those with CR/PR and PD: 26% (5 of 19) of PD samples had
>50% of SNVs with variant gain (SD: 0 of 13), while 38% (5 of 13) of SD samples had
>50% of SNVs under variant loss (PD: 0 of 19) (Figure 2A).

Author Manuscript

Excluding patient 3, all patients with CR/PR consistently lost one or more clones ontherapy; conversely, patients with SD and PD gained novel sets of mutations on-therapy
(Figures 2A and 2D). For example, patient 27 (PD) and patient 10 (SD) both had a dominant
clone, at least one smaller subclone at initiation of therapy, and the emergence of a novel
subclone in the on-therapy sample. In addition, patient 10 had a subclone that was lost after
treatment (Figure 2D). Losses were more common in patients with SD than PD. On
aggregate, novel subclonal variants were often due to mutational signature 11, which has
previously been associated with melanoma and exposure to temozolomide (Alexandrov et
al., 2013), and in this setting, suggests that a specific type of repair process becomes
dysfunctional due to immunotherapy-mediated stress (Figure S2G).
Transcriptome Analysis and Changes during Treatment

Author Manuscript

Pre-therapy Expression Analysis Identified Pre-existing Immune Programs in
Responders and Expression Footprints of “Hot” versus “Cold” Tumors Based
on Prior Immunotherapy Exposure—Baseline transcriptional programs using RNA
sequencing (RNA-seq) were characterized and associations with clinical response
investigated (n = 45; Table S4). Analysis of differentially expressed genes (DEGs) between
patients with CR/PR and PD identified 189 DEGs (q < 0.20; Figure 3A). Highly expressed
genes were immune-related, which suggests pre-existing immune recognition of the tumor;
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however, Gene Ontology (GO) analysis using the Reactome database only identified highlevel categories such as T-cell activation and lymphocyte aggregation as enriched (q < 0.1;
Figure S3A). Notably, this group included IL17RE, IL17RC and FGFR3 (Table S6A), which
modulate the immune environment (Sweis et al., 2016). Next, pre-existing signatures of
immune response were evaluated by immune deconvolution (see Methods). A pre-existing
immunologically active or “hot tumor” environment was observed in all Ipi-P patients with
CR/PR, whereas variable immunological activity was observed in Ipi-N patients with CR/PR
(Figures 3B and S3B). No association between the previously reported IPRES gene
signature and response was seen in this cohort or in another cohort previously described
(Hugo et al., 2016) (Figure S3C).

Author Manuscript

On-therapy Genomic Contraction Phenotype Correlated with Pre-existing
Immunity in Responders—We hypothesized that a molecular phenotype of response,
such as tumor genomic contraction/persistence, ascertained at an early time-point, such as 4
weeks (Figure 2C), may more strongly correspond to underlying biologic changes than
would clinical assessments of response. Differential gene expression analysis between
patients who had genomic contraction and genomic persistence was performed to examine
pre-existing differences in immunity pre-therapy. In the cohort of 26 patients with paired
WES and RNA-seq, 695 DEGs were observed (q < 0.10; Figure 3C and Table S6B), of
which 565 had a fold change greater than two. Clustering analysis of all patients and other
checkpoint-blockade-treated cohorts demonstrated that this set of immune-related genes
stratified patient survival (Figure 3D).

Author Manuscript

Gene set enrichment analysis demonstrated enrichment of genes involved in PD-1 signaling,
co-stimulation of the CD28 family, downstream T-cell receptor (TCR) signaling, IFN-γ, and
IL-2 signaling (q < 0.1; Figure S3D). Although PD-1 signaling was enriched, neither
PDCD1 (PD-1) nor CD274 (PD-L1) were differentially expressed. However, components of
the TCR immunological synapse were enriched (e.g., CD3D/E/G, PTPN6, CD247, CD28,
CD86). Notably, several HLA class II alleles were differentially regulated between the two
groups, in addition to genes associated with PI3K-γ signaling by G protein–coupled
receptors (Figures S3D and S3E).

Author Manuscript

On-therapy Analysis of Tumor Transcriptome—We subsequently hypothesized that
anti-PD-1 therapy can induce tumor transcriptional and microenvironmental sculpting
associated with response and therefore evaluated how the expression landscape of melanoma
is altered during Nivo therapy. To identify expression changes indicative of a
“pharmacologic response” to Nivo, expression of genes that significantly change on-therapy,
regardless of response, were analyzed. 475 DEGs were identified in on-therapy samples (q <
0.20; Figure 4A and Table S6C), most of which were associated with immune regulation as
determined by Ingenuity Pathway Analysis (IPA) (Figure S4A). Many immune checkpoint
genes increased in expression, regardless of response to therapy, including PDCD1 (PD-1),
CD274 (PD-L1), CTLA-4, CD80 (CTLA-4-L), ICOS, LAG3, and TNFRSF9 (4-1BB).
Matched pre- and on-therapy samples were examined to determine whether relative
differences in gene expression changes on-therapy could distinguish between patients whose
disease was controlled and patients with PD. 2670 DEGs were identified between pre- and
Cell. Author manuscript; available in PMC 2018 November 02.

Riaz et al.

Page 7

Author Manuscript

on-therapy samples of responders and non-responders (q < 0.20; Figure 4B; Table S6D).
Upregulated genes in responders involved a broader spectrum of immune-related genes than
genes solely identified in pre-therapy samples (Figures S4B and S4C); including additional
checkpoint-related genes (TNFRSF4 [OX40], TIGIT, HAVCR2 [TIM-3], and C10orf54
[VISTA]), and genes involved in lymphocyte activation, chemotaxis and cytokine signaling,
and immune cytolytic activity, consistent with previous findings (Das et al., 2015).
Downregulated genes in responders involved pathways related to tumor growth, including
neural and melanin pathways, cell-cycle regulation, mitotic division, and translation (Figure
4C). Significantly more immune-related genes were selectively upregulated in responders
than in non-responders (p = 6.17e–3 and p = 4.61e–4 for depletion in the inflammatory
response and cytokine-mediated signaling pathways from GO, respectively).

Author Manuscript

Changes in immune subpopulations between pre-therapy and on-therapy samples were
assessed by immune-deconvolution analysis (see Methods) and numerous changes in
immune response among different tumors were observed. An increase in number of CD8+ T
cells and NK cells, and a decrease in M1 macrophages, associated with response to therapy
(Figure 4D).
T-Cell Repertoire Analysis and Immune Checkpoint Therapy

Author Manuscript

How Nivo therapy influences T-cell repertoires was examined by analysis of changes in the
T-cell abundance, activation, and diversity. We also evaluated how these anti-PD-1-induced
changes are affected by prior immunotherapy exposure. To study the dynamics of T-cell
infiltration and repertoire diversity in response to Nivo, next-generation deep sequencing of
TCR β-chain complementarity determining regions (CDR3s) (TCR-seq) was performed on
tumor samples pre- and 4 weeks post-Nivo initiation (n = 34; Table S4). From these
nucleotide sequences, the repertoire of amino acid motifs that determine the specificity of
antigen-binding and their relative abundances were tabulated (see Methods). Due to the
limited number of samples for which TCR-seq data was available, we grouped patients as
those with benefit (CR, PR, and SD) or no benefit (PD).

Author Manuscript

Changes in T-Cell Tumor Infiltration and Activation Associated with Prior
Treatment Status and Clinical Response—The fraction of TILs present within each
tumor (the proportion of sample that is infiltrating lymphocytes) was assessed by both TCRseq and immunohistochemical (IHC) staining for CD3 on mostly non-overlapping cohorts of
patients (Table S4). By both approaches, an increase in the fraction of TILs upon Nivo
therapy was significantly greater among benefiting than non-benefiting Ipi-N but not Ipi-P
patients (TCR-seq, p = 0.040; IHC, p = 0.023). Despite the differences in T-cell infiltration,
increased cytolytic pathway genes (Rooney et al., 2015) as measured by RNA-seq were
associated with benefit to Nivo in both Ipi-P and Ipi-N cohorts (p = 0.043 and p = 0.005;
Figure 5A). Notably, there was no significant difference in TIL abundance pre-therapy
between patients with benefit and no benefit, or between Ipi-N and Ipi-P cohorts (Figure
S5A).
On-therapy Changes in Intratumoral T-Cell Repertoire Diversity Associated
with Response Differentially between Ipi-P and Ipi-N Patients—The diversity of
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the CDR3 repertoire can be characterized by the Shannon entropy metric, which has two
components: the number of unique CDR3s (richness) and their equality of distribution
(evenness) (see Methods). Pre-therapy, no significant difference in either of these metrics
was observed between cohorts or response status (Figures S5B and S5C). On-therapy, the
median fold change in the number of unique CDR3 sequences (richness) was significantly
associated with benefit in Ipi-P but not Ipi-N patients (p = 0.016 versus p = 0.489; Figure
5B). In contrast, the median change in T-cell evenness on-therapy was associated with
benefit in Ipi-N but not Ipi-P patients (p = 0.036 versus p = 0.594; Figure 5B).

Author Manuscript

To refine interpretation of these findings with respect to the antigen-binding properties of the
TCR repertoire, the diversity of the CDR3 amino acid sequences encoded by a single VJ
cassette combination was analyzed individually for every observed VJ combination (see
Methods). Notably, a significant decrease in median CDR3 evenness per VJ group ontherapy was observed in Ipi-N but not Ipi-P patients (p = 0.006 versus p = 0.600 Figures 5C
and 5D) and in benefiting but not non-benefiting patients (p = 0.003 versus p = 0.636;
Figures 5D and S5D). When stratified by both prior treatment status and response, the fold
change in CDR3 richness per VJ combination was associated with benefit in Ipi-P but not
Ipi-N patients (p = 0.014 versus p = 0.287; Figure S5E), while a significant decrease in
CDR3 evenness per VJ pair was observed in Ipi-N but not Ipi-P benefiting patients (p =
0.020 versus p = 0.131; Figure S5D). These results, derived from CDR3 subsets grouped by
VJ combination, are mostly consistent with the trends of bulk CDR3 populations (Figure
5B). This suggests, due to association with CDR3 amino acid sequences rather than VJ
cassette identities, that T-cell population diversity dynamics are driven substantially by
antigen recognition.

Author Manuscript

To visualize these changes in CDR3 diversity within each VJ combination, CDR3 evenness
per VJ versus number of CDR3s per VJ were plotted for every VJ cassette group pre- and
on-therapy as kernel density plots (Figure 5D). In the Ipi-N cohort, rightward shifts along
the x-axis represent increases in CDR3 richness per VJ combination on-therapy and
downward shifts along the y-axis represent decreases in CDR3 evenness per VJ combination
on-therapy. Notably, the shifts in evenness and richness per VJ are less prominent in the IpiP cohort.

Author Manuscript

Integrated T-Cell Abundance and Diversity Metrics Associated with Response
—Due to the diversity of the TCR repertoire in circulating blood (Zarnitsyna et al., 2013),
increased T-cell infiltration is usually concomitant with an increase in the observed diversity
of that TIL repertoire. To understand whether the changes observed in the TIL CDR3
repertoires during Nivo therapy were primarily a function of the degree of infiltration or
were due to clonotype distribution changes, indicative of selection and expansion of T-cell
clonotypes, the minimum percentage of unique CDR3 sequences accounting for 90% of the
sequencing reads (D90) was calculated for each TIL sample. D90 is an indicator of evenness
in which lower values indicate a more skewed distribution. While the evenness of most Ipi-P
TIL repertoires did not change on-therapy, evenness varied widely among Ipi-N patients
(Figure 5E). D90 value versus the level of TIL infiltration showed that in Ipi-N patients,
disease control was greater among patients with lower TIL D90, including several with low
TIL infiltration, such as patients 10, 89, and 94 (Figure 5E). This likely reflects the
Cell. Author manuscript; available in PMC 2018 November 02.
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expansion of specific clonal populations in Nivo responders. This behavior contrasted with
that of the Ipi-P cohort, in which high fractional TIL levels during Nivo therapy were a
strong indicator of disease control, but CDR3 diversity varied relatively little (Figures 5E
and S5A). Furthermore, usage of CD8-associated V-segments (Emerson et al., 2013) was
significantly correlated with response (p = 0.005; ordinal regression), while CD4-associated
V-segments were not (p = 0.329; ordinal regression; Figure 5F).
Integrative Analysis of Tumor and T-Cell Dynamics

Author Manuscript

Changes in T-Cell Diversity Associate with Tumor Neoantigen Landscape—We
next assessed how the underlying changes in T-cell clonal dynamics related to changes in the
clonal dynamics of the tumor. Changes in T-cell repertoire evenness were directly
proportional to changes in the fraction of clonal mutations in patients with CR/PR and PD.
Notably, there was a trend for a positive relationship in responders (p = 0.07), but a negative
relationship in patients with PD (p = 0.08; Figure 6A). We therefore evaluated the
relationship between the number of T-cell clones that expanded on-therapy and the number
of neoantigens that became undetectable on-therapy. In patients with CR/PR there was a
linear relationship between the number of expanded T-cell clones and the number of
neoantigens that became undetectable on-therapy (p = 0.03) (Figure 6B; Table S5B).
Notably, this did not occur in patients with SD or PD, suggesting a qualitative difference in
the T-cell response in these tumors. Similar results were obtained when considering clonal
mutations that became undetectable on-therapy, pre-therapy mutation load, or genomic
contraction/persistence cases, supporting the view that T-cell expansion is related to the
underlying genetic profile of the tumor (Figures S6A–S6C).

Author Manuscript

Selective Depletion of Antigenic Mutations On-therapy in Responding Patients
—To investigate whether mutations that were undetectable on-therapy were more likely to
be neoantigens or missense mutations than nonantigenic or synonymous mutations, the
neoantigen ratios of mutations that produce predicted neoantigens to those that do not were
compared between mutations detected solely on-therapy and those detected solely pretherapy. We hypothesized that the ratio of neoantigen-producing mutations would be higher
pre-therapy versus on-therapy in patients with an active immune response, indicating
selective pressure against the generation of antigenic mutations. Patients with CR/PR had
lower neoantigen ratios on-therapy than patients with PD (p = 0.03; Wilcoxon rank-sum
test), and patients with SD had a borderline association (p = 0.11; Wilcoxon rank-sum test;
Figures 6C and S6D).
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To evaluate the possibility of selective depletion of putative neoantigens within each
individual patient, the pre-therapy number of neoantigens per synonymous mutation was
determined, and the expected number of neoantigens on-therapy was computed using the
measured number of on-therapy synonymous mutations (see Methods). In patients with
CR/PR, the observed number of neoantigens was lower than the expected value (p < 0.05;
Figure S6E), suggesting that T cells were effective in eliminating tumor cells expressing
immunogenic neoantigens.
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DISCUSSION
Previous reports indicate that increased tumor mutation load is associated with response to
immune checkpoint therapy and that this relationship improves with assessment of clonality
(McGranahan et al., 2016; Rizvi et al., 2015; Snyder et al., 2014). We observed an
association of pre-therapy tumor mutation load and clonal mutation load with survival and
response; however, this observation was limited to the Ipi-N subset of patients, consistent
with previous findings (Weber et al., 2016a). Ipi-P patients had significantly more subclonal
mutations present, and neither of these genomic markers correlated with response to therapy
in these patients. These findings suggest that current biomarkers used to determine which
patients will respond to immunotherapy may be more useful for Ipi-N patients than Ipi-P
patients, though larger studies will be necessary to confirm these findings.

Author Manuscript
Author Manuscript

After 4 weeks of Nivo therapy, we observed a marked decrease in detectable mutations
among patients with CR/PR and a moderate decrease in patients with SD. Clonality analysis
identified that Nivo therapy affects the evolutionary landscape of tumors in patients with
CR/PR, leading to the collapse of whole clonal populations, while in patients with SD, Nivo
may shift the landscape in favor of specific subclones. Notably, in several patients with SD,
some subclones became undetectable while others remained. In addition, we demonstrated
genomic evidence of effective immune elimination of tumor cells containing nonsynonymous mutations and neoantigens on-therapy in responding patients as a group, and in
a subset of responding patients individually. Moreover, T-cell clones expanded in proportion
to the number of neoantigenic mutations that became undetectable on-therapy. These
observations agree with evidence of immune-mediated genetic loss of patient-specific
mutations, such as after adoptive T-cell therapy (Verdegaal et al., 2016). Our genetic data are
consistent with immunoediting, and are derived from a larger group of patients than
previously studied (Verdegaal et al., 2016). However, we cannot make definitive conclusions
due to computational limitations; namely, unambiguous identification of specific
neoantigens driving this effect.

Author Manuscript

Therapy-induced clonal evolution has been reported following other cancer therapies such as
cytotoxic treatments in glioblastoma (GBM) and chronic lymphocytic leukemia, and our
observation of CDKN2A loss in four patients with PD agrees with reported changes in GBM
tumors at progression (Johnson et al., 2014; Landau et al., 2015). The appearance of new
mutations on-therapy could represent genetic drift, or alternatively could be consistent with a
model in which certain subclonal populations are selected under immunologic pressure.
However, on-therapy expression analysis indicates that an immune ignorance or immune
exclusion mechanism of resistance is likely operative rather than the evolution of an intrinsic
genetic mechanism mediating resistance. The early collapse in clonal populations among
responding patients is consistent with previous findings (Landau et al., 2015; Wang et al.,
2016), and suggests that clonal composition undergoes significant changes after cytotoxic
therapy. Our results may potentially be affected by variation in the anatomic location from
which the tissue was taken and by intratumoral heterogeneity, and by decreased purity in ontherapy biopsies; however, biopsies targeted the same site and, although purity did decrease
on-therapy, the magnitude of change was not large enough to explain observations herein.
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Expression analysis of pre-therapy tumor samples identified a small set of upregulated
immune-related genes in responders, consistent with prior reports demonstrating an IFN-γ
signature associated with response (Taube et al., 2012; Taube et al., 2015). However, these
expression changes were only marginally predictive of response. Notably, consistent with
previous findings (Larkin et al., 2017; Weber et al., 2016b), of patients who received prior
immunotherapy, only those with PD-L1-expressing or immunologically “hot tumors”
appeared to respond whereas significant responses were observed among PD-L1 low to no
expression subgroups among Ipi-N patients. These findings may again be limited due to the
size of the cohort but, like mutation load and tumor clonality, suggest that the importance of
a “hot tumor” may depend on prior therapy received.
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Surprisingly, stratification based on a molecular phenotype of response (i.e., genomic
contraction/persistence) demonstrated a more pronounced difference in pre-existing
immunity between molecular responders and non-responders. Genes differentially expressed
between groups could predict survival in other patients in this dataset and in other
immunotherapy-treated cohorts, signifying their biologic relevance and suggesting that
delays in clinical response may be secondary to immune infiltration (Wolchok et al., 2009).
This highlights the difficulty in relying solely on clinical and radiographic response to
understand the underlying biologic mechanisms of response to therapy in human tumors.
Notably, this analysis identified numerous HLA class II genes, along with other genes, as
differentially expressed, similar to a recently reported signature indicating differences in
regulation of macrophages (Kaneda et al., 2016). Changes in macrophages on-therapy also
associated with clinical response (Figure 4D), suggesting that macrophages may play an
important role in response (Gordon et al., 2017).
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Analysis of on-therapy expression changes revealed marked upregulation of a multitude of
immune pathways that were more pronounced in responding patients, and included
additional checkpoints and a broader set of DEGs than previously reported (Chen et al.,
2016). Some of these newly identified gene products may be considered as candidate targets
for future combination immunotherapy trials. Most patients with PD had minimal immune
response on-therapy, and differential gene analysis did not identify a dominant or single
method of tumor-intrinsic immune evasion, suggesting an immune ignorance or immune
exclusion mechanism rather than an adaptive resistance mechanism (Salerno et al., 2016;
Spranger et al., 2013) (Figure 4B). In contrast, many patients with SD appeared to have
modest immune response induction, suggesting that an adaptive mechanism of resistance
may have a more important role in these patients (Taube et al., 2012; Taube et al., 2015).
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Increased cytolytic activity, indicative of T-cell activation, associated with response. Both
cytolytic activity and response were observed at similar rates regardless of prior immune
therapy exposure. However, analysis of T-cell repertoires suggested that anti-PD-1 response
is associated with different patterns of T-cell diversity dynamics in Ipi-N versus Ipi-P
patients. We infer that decreased evenness without a significant change in the total number
of CDR3s (richness) observed in Ipi-N responders is consistent with expansion and
accumulation of specific T-cell clonotypes in response to the detection of tumor antigens.
We speculate that TILs of Ipi-P patients may represent a binding repertoire already
differentially selected by the tumor antigenic landscape during Ipi treatment, but
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subsequently exhausted through PD-1/PD-L1 signaling. The predictive value of exhaustion
marker expression for responsiveness in Ipi-P but not Ipi-N patients is consistent with this
model (Figure 3B). Thus, we speculate that in Ipi-P patients, anti-PD-1 therapy functions
mainly by alleviating exhaustion among the extant distribution of TIL clonotypes, while in
Ipi-N patients, anti-PD-1 therapy facilitates selective intratumoral expansion of tumorreactive clonotypes (Figure 6D).
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We hypothesize that changes in T-cell repertoire diversity are associated with anti-PD-1induced intratumoral clonal architecture changes, reflecting the cytolytic anti-tumor effect of
expanded tumor antigen-specific T-cell clonotypes. Of note, changes in T-cell repertoire
evenness were directly proportional to changes in the fraction of clonal mutations in
responders and patients with PD. There was a trend for a positive and negative relationship
in responders and non-responders, respectively, suggesting that in responders, as T-cell
clones expand, clonal mutations are targeted and eliminated. Possible explanations for the
negative relationship in non-responders include: (1) T-cell clonotypes that expand may target
subclonal mutations instead of clonal mutations, resulting in a futile T-cell response (Figure
S6F), or (2) decreased T-cell repertoire evenness could be due to clonal expansion of
regulatory T cells, which may enhance an immunosuppressive environment.
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In conclusion, we performed extensive immunogenomic analyses on melanoma samples
treated with anti-PD-1 therapy and characterized how tumor genomic and
microenvironmental features changed over time. Assessment of the genomic landscape ontherapy demonstrated clonal evolution consistent with therapy-dependent immunoediting. Tcell repertoire analysis identified that T-cell clonotypes expand in proportion to the number
of neoantigens that become undetectable in responding patients. Gene expression analysis
revealed the changing transcriptional and microenvironmental alterations induced by antiPD-1 therapy and identified a broad spectrum of immune checkpoint-related genes that were
upregulated. These data have important implications for understanding the mechanism of
action of checkpoint inhibitors and for the design of future immune checkpoint blockade
trials. Based on our observations, we propose a model of tumor evolution and its
microenvironment in response to anti-PD-1 therapy (Figure 6D).

STAR METHODS
CONTACT FOR REAGENT AND RESOURCE SHARING

Author Manuscript

Further information and requests for resources and reagents should be directed to and will be
fulfilled by the Lead Contact, Timothy Chan (chant@mskcc.org). Sequencing data may be
accessed, on approval, by individual investigators upon request (https://fasttrack.bms.com
and christine.horak@bms.com).
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Eighty-five patients were accrued to a multi-arm, multi-institutional, institutional-reviewboard-approved, prospective study (CA209-038; NCT01621490) to investigate the
pharmacodynamic activity of Nivo. All patients received Nivo (3 mg/kg every 2 weeks) until
progression or for a maximum of 2 years. Radiographic assessment of response was
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performed approximately every 8 weeks until progression. Progression was confirmed with
a repeat CT scan typically 4 weeks later. Tumor response for patients was defined by
RECIST v1.1. Response to therapy indicates best overall response unless otherwise
indicated. All patients underwent biopsy before commencing therapy (1–7 days before first
dose of therapy) and underwent a repeat biopsy, collected from the same site, on cycle 1, day
29 (between days 23–29). Tumor tissue was divided for FFPE and storage with RNAlater®
(Ambion) for subsequent RNA/DNA extraction. Of 85 patients, 68 had sufficient material
for genomic analysis. 35 of 68 patients were Ipi-P and 33 were Ipi-N. Different subsets of
patients had sufficient material for the different genomic analysis described (Tables S2 and
S4). Of the 68 patients studied, the median patient age was 55 years (range 22–89) and
consisted of 1 M0, 13 M1a, 10 M1b, 36 M1c and 8 patients with unknown stage at study
entry.

Author Manuscript

METHOD DETAILS

Author Manuscript

Whole-Exome Sequencing—DNA was extracted from samples stored with RNAlater®
and sequenced with next-generation sequencing. Sequencing libraries were generated using
Illumina’s in-solution DNA probe based hybrid selection method as previously described
(Fisher et al., 2011). Exonic sequences were enriched using Agilent SureSelect All Exon V2.
Pooled libraries were normalized to 2 nM and denatured using 0.2 M NaOH prior to
sequencing. Sequencing was performed per manufacturer’s protocols using either the HiSeq
2000 V3 or HiSeq 2500. Each run was a 76bp paired-end with a dual eight-base index
barcode read. Alignment and removal of duplicates was performed as previously described
(Riaz et al., 2016b). A combination of four different mutation callers (MuTect 1.1.4,
SomaticSniper 1.0.4, VarScan 2.3.7, and Strelka 1.0.13) were used to identify SNVs. SNVs
with an allele read count of less than 5 or with corresponding normal coverage of less than 7
reads were filtered out as previously described (Riaz et al., 2016b). Small insertions and
deletions (indels) were determined using VarScan 2.3.7 and Strelka 1.0.13. Mutation load
was determined as the number of remaining non-synonymous mutations. A previously
published cutoff of 100 mutations was used to segregate high from low mutation-load
tumors (Snyder et al., 2014). Only high- or moderate-impact indels determined by both
callers were selected. Mutational subtypes of melanoma were determined using the TCGA
classification system. Previously described signatures of mutational processes were
determined in each sample using non-negative least squares regression as provided by the R
package deconstructSigs v1.8.0 using the COMISC signatures as the mutational signature
matrix.
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Neoantigen Analysis—High-resolution HLA typing was performed computationally
using SOAP-HLA from exome sequencing (exome-seq) data. Each non-synonymous SNV
was translated into a 17-mer peptide sequence, centered on the mutated amino acid.
Adjacent SNVs (such as those induced by UV irradiation) were first corrected for using
MAC. Subsequently, the 17-mer was then used to create 9-mers via a sliding window
approach for determination of MHC class I binding. NetMHC v4.0 was used to determine
the binding strength of mutated peptides to patient-specific HLA alleles. All peptides with a
rank <2% were considered for further analysis. If one mutation generated multiple 9-mer
peptides that bound to patient-specific HLA alleles, it was only counted as one neoantigen
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(i.e., one mutation could only generate a single predicted neoantigen). We considered
neopeptides as the total number of predicted 9-mers that bound to patient-specific HLA
alleles (i.e., one mutation can generate multiple neopeptides).
To test whether the observed number of neoantigens was different from the expected count
in each on-therapy tumor sample, we empirically calculated the following baseline rates pretherapy:
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1.

The average number of missense mutations per silent mutation across tumors.

2.

The number of neoantigens per missense mutation. Of note, since computational
tools that predict neoantigens are dependent on patient-specific HLA class I
alleles and some HLA-I alleles can bind greater numbers of peptides than others,
we calculated this rate specific to the patient, rather than an average across all
patients.

Using these two baseline rates, we used the number of silent mutations in each on-therapy
tumor sample to calculate the expected number of neoantigens. Hence, the expected number
of neoantigens in an on-therapy tumor sample is equal to the number of silent mutations in
an on-therapy tumor sample multiplied by the number of missense mutations per silent
mutation pre-therapy, multiplied by the number of neoantigens per missense mutation in the
patient’s tumor sample pre-therapy. The chi-squared test was used to determine whether the
observed number was different from the expected value. All the calculations were done
using R statistical software

Author Manuscript

Copy-Number Analysis—Allele-specific copy-number analysis was performed from
exome-seq data using FACETS v0.5.0 with a critical value of 300 to increase the strictness
of segments. The fraction of the copy-number-altered genome was defined as the fraction of
the genome with either non-diploid copy-number or evidence of loss of heterozygosity.
Homozygous copy-number alterations in CDKN2A, NF1, PTEN, and B2M were manually
reviewed and, when available, confirmed with corresponding expression changes. Recurrent
copy-number alterations for melanoma as determined by GISTIC were downloaded from
The Broad Firehose on January 28, 2016, and evaluated in each sample for presence or
absence using copy-number data generated by FACETS.
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We additionally assessed genomic instability as previously described (Davoli et al., 2017).
Each genomic segment in the FACETS output was assigned a somatic copy-number
alteration (SCNA) level on a five-tier scale based on the total copy-number (tcn) and sampleploidy values. Specifically, a ploidy-adjusted tcn value, T, was computed by rounding the
sample’s ploidy value to the nearest whole number and subtracting it from the tcn.em value
(calculated by FACETS software EM algorithm). Genomic segments were classified as
below:

SCNA Level

SCNA Event

Ploidy-Adjusted tcn

2

Deep amplification

T≥3
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SCNA Level

SCNA Event

Ploidy-Adjusted tcn

1

Amplification

3>T≥1

0

Neutral

1 > T > −1

−1

Deletion

−1 ≥ T

−2

Deep deletion

Ploidy = −T

Author Manuscript

Chromosomal, chromosome-arm and focal SCNA scores were derived for each sample.
SCNA events were determined to be chromosomal if segments with the same SCNA level
accounted for at least 75% of the total length of FACETS segments for a given chromosome.
Segments determined not to be part of a chromosomal event were next evaluated as
potentially contributing to chromosome-arm events by checking if genomic segments
sharing the same SCNA level overlapped with at least 75% of the chromosome arm’s
coordinates. Segments determined not to be contributing to chromosomal events or to
chromosome-arm events were defined as focal SCNA events if their individual lengths were
less than half the length of chromosome arms on which they were located. SCNA scores for
each level were computed by individually summing the absolute values of the chromosome,
arm and focal events. SCNA scores were normalized across all samples using the mean and
standard deviation. An additional SCNA score was computed by adding the normalized
chromosome and arm level SCNA scores.
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Tumor Clonality Analysis—We determined the CCF of mutations identified in each
tumor sample using PyClone v0.13.0, as previously described (Morris et al., 2016). For each
SNV, CCF was estimated based on reference and variant allele read counts as well as allelespecific copy-number information determined by FACETS as described above. Tumor purity
was also estimated using FACETS and provided as an input to PyClone. The infinite beta
binomial mixture model with default priors was fit after 10,000 iterations. As in previous
work, we considered mutations to be clonal if the 95% confidence interval (CI) of the CCF
contained 95% (McGranahan et al., 2015). The CCF was calculated for every SNV in a
sample and represents an estimate of the fraction of cancer cells carrying that mutation. The
CCF was calculated for each SNV separately based on variant allele frequencies (VAFs),
copy-number status (amplifications/deletions), ploidy of the genome, and purity of the
sample, and can be interpreted as an adjusted VAF, which allows comparison of SNVs
across different samples. We classified SNVs into clonal and subclonal variants depending
on the CI of the CCF estimation. SNVs for which the lower bound of the CI exceeded 95%
were considered clonal mutations, others subclonal. A comparison based on CCFs
determined by ABSOLUTE provided similar results (data not shown) (Carter et al., 2012).
High versus low clonal mutation load was split at the median of the clonal mutation load for
the cohort.
SNVs were considered to indicate genomic expansion if their subclonal CCF increased by at
least 10% from pre- to on-therapy sample or if they were novel to the on-therapy sample and
did not occur in pre-therapy sample. SNVs indicating genomic contraction decreased by
≥10% CCF or were only identified in the pre-therapy sample but not in the on-therapy
sample. SNVs that occurred at clonal or subclonal CCFs within 10% of pre- and on-therapy
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samples were not considered to indicate mutational changes and referred to as genomic
persistence. A comparison of the selective pressure per sample, was defined as the fraction
of mutations undergoing genomic contraction subtracted from the fraction of mutations
undergoing genomic persistence. This metric was used for subsequent survival analysis and
RNAseq differential gene expression analysis.
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RNA Sequencing—RNA was extracted from tissue specimens stored using RNAlater®.
Raw FASTQ files were aligned on the hg19 genome using the STAR aligner with default
parameters. Aligned fragments were then counted and annotated using Rsamtools v3.2 and
the TxDb.Hsapiens.UCSC.hg19.knownGene transcript database, respectively. Normalized
fragments per kilobase per million mapped reads (FPKM) were obtained using the robust
FPKM estimate function of DESeq2 v1.12.4. Raw reads were normalized with regularizedlogarithm transformation function with robust estimation and used to construct a PCA plot,
which was manually reviewed. Patient 3 was considered an outlier (data not shown) and thus
removed from subsequent transcriptome analysis. All differential gene analysis was
conducted using the DESeq2 package.
Differential gene expression analysis was performed using a generalized linear model with
the Wald statistical test, with the assumption that underlying gene expression count data
were distributed per a negative binomial distribution with DESeq2. DEGs were considered
for further analysis with a q-value <0.20. Clustering of DEGs was conducted with hierarchal
clustering (Euclidean distance followed by Ward agglomeration algorithm) primarily to
segregate upregulated and downregulated genes.
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For pre-therapy samples, we considered DEGs between responders (CR/PR) compared with
non-responders (PD) or patients with SD without adjusting for any other parameters. For
analysis of pharmacologic response, we compared the subset of samples with paired on- and
pre-therapy RNA-seq to identify genes that had changes in expression on-therapy. We
grouped patients as those who benefited (CR/PR/SD) and those who had no benefit (PD) to
identify genes that changed differentially. Design matrices for each analysis are available in
supplementary code available on GitHub.
GO enrichment analysis was performed with the R package clusterProfiler, with a
Bonferroni correction and an adjusted p-value of 0.20 (Yu et al., 2012). Fold changes from
analysis of RNA-seq data were inputted to IPA. The IPA downstream effects analysis was
used to identify differentially regulated pathways.
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Cytolytic activity was determined as the geometric mean of genes GZMA and PRF1 as
previously described (Rooney et al., 2015). Similarly, a signature of IFN-γ was determined
for each sample set using a set of genes previously described (Chiappinelli et al., 2015). To
further refine subsets of immune cells that were present in each sample, CIBERSORT was
used to conduct immune deconvolution on the FPKM values of each patient.
TCR β-Chain Sequencing and Analysis—Tumor biopsy samples were collected prior
to and 4 weeks after initiation of Nivo therapy and stored in RNAlater®. DNA was extracted
and submitted to Adaptive Biotechnologies for survey level TCR β-chain sequencing
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(Carlson et al., 2013; Robins et al., 2009), where targeted amplicon libraries were prepared
by multiplex PCR targeting all TCR β-chain V and J gene segments, and sequenced using
the Illumina HiSeq system. Data for individual TCR sequences, including V and J gene
segment identification and CDR3 sequences, were obtained from Adaptive Biotechnologies
for customized analysis of T-cell repertoire diversity dynamics.
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Population diversity of the T-cell repertoire can be characterized and quantified by two
separate factors: richness (i.e., the number of unique elements in a population), and evenness
(i.e., the distribution of the frequencies of those elements). Shannon entropy (H) takes into
account both richness and evenness, but gives more weight to evenness (Arnaud-Haond et
al., 2007). Evenness is defined as the observed H divided by the maximum possible H, given
the number of unique elements in a population. High evenness (on a scale of 0 to 1) implies
that all elements are nearly equally distributed, while low evenness is indicative of
population skewing, or, in the case of TCR repertoire analysis, biased expansion of
individual T-cell clonotypes (Arnaud-Haond et al., 2007; Six et al., 2013). Clonality is
defined as the complement of evenness (i.e., 1 – evenness). As such, these terms are used
somewhat interchangeably, but with reversed scales. Note that for analysis of evenness, two
outlier cases were removed as determined by Grubbs’ Test, alpha = 0.1.
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The protein-binding characteristics of the CDR3 antigen-binding region of the TCR can be
studied in a more targeted way by analyzing the repertoire of amino acid CDR3 sequences
encoded by each combination of V and J cassettes. To explore whether the global TCR
diversity dynamics described above could also be detected at the level of individual VJ
cassette combinations, we determined CDR3 richness and evenness for every VJ pair, as
previously described (Sims et al., 2016). This approach, although more rigorous, is an insilico descendant of traditional spectratyping, in which specific V and J cassette primers are
used to amplify all CDR3s encoded by specific VJ cassette combinations and the products
are analyzed by electrophoresis (Arstila et al., 1999). The benefits of this in-silico approach
are two-fold: 1) by examining diversity dynamics at the VJ cassette level, bias potentially
introduced by preferential V and J cassette primer binding is diminished, and 2) a greater
understanding of the extent to which antigen-binding properties (CDR3 amino acid
sequences) versus VJ cassette usage biases influence global changes in TCR diversity is
gained (Sims et al., 2016). Kernel density estimate plots of the number of CDR3s per VJ
versus evenness of CDR3s per VJ were generated using the seaborn statistical data
visualization platform for Python.
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Significantly expanded T-cell clones were identified using the immunoSEQ® Analyzer from
Adaptive biotechnologies®, per the method previously described (DeWitt et al., 2015);
briefly, Fisher’s exact test was used to generate a p-value by for every T cell clone, and Pvalues were corrected using a positive false discovery rate method to identify significantly
expanded T-cell clones.
Immunohistochemistry—PD-L1 staining was evaluated centrally by IHC using a rabbit
monoclonal anti-human PD-L1 antibody (clone 28-8) and an automated staining procedure
developed by Dako (Dako, 2016). The percentage PD-L1 expression was scored by a
qualified pathologist in samples with a minimum of 100 viable tumor cells. Positive PD-L1
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staining was defined as complete circumferential or partial linear plasma membrane staining
of tumor cells. Expression of lymphocytic markers within tumor tissue sections was
centrally assessed by IHC using antibodies against CD3, CD4, CD8 and FOXP3: clone
LN10 (Leica), clone 4B12 (Dako), clone C8/144B (Dako) and clone 236A/E7 (Abcam),
respectively. Duplex chromogenic IHC assays consisting of CD3 and CD8, CD3 and CD4,
and CD3 and FOXP3 anti-human antibodies were established. Percentage expression of each
marker was estimated using digital image analysis algorithms from multispectral images of
representative 20 fields in a region of interest that included cancer cells.
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Tumor Purity Assessment—Tumor purity was assessed computationally in all paired
samples using estimates derived from exome-seq data and from RNA-seq data
independently using OncoSNP-SEQ and ESTIMATE. There was a modest decrease in tumor
purity in samples with a more significant clinical response than those with PD using any of
the three methods for estimation of purity (Figure S2D).
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We performed a simulation to determine our power to detect a mutation, assuming a fivefold decrease in purity. We assumed that to accurately call a mutation, five reads with the
mutation needed to be present and reads were distributed according to a binomial
distribution (B(n,p)), where n corresponds to the coverage of sequencing and p the true VAF
of the mutation. At 150× coverage we had 95% power to detect a mutation with a VAF of
6% or greater and at 300× coverage we had 95% power to detect a mutation of 3% VAF or
greater in any one sample (Figure S2E). We then computed the proportion of mutations we
would anticipate to detect using 300× coverage and a fivefold decrease in purity and
observed a significant depletion in the number of anticipated mutations in most cases
(Figure S2F). In all cases, the expected number of mutations was larger than the observed,
which is unlikely given a five-fold decrease in purity (p = 0.004; Wilcoxon rank-sum test).
QUANTIFICATION AND STATISTICAL ANALYSIS
Statistics and Survival Analysis—Survival analysis was conducted with the Kaplan–
Meier method, and continuous data were in general split at the median, unless prior
thresholds had been established. The log-rank test was used to determine statistical
significance. Comparison of values between response groups was performed with the
Wilcoxon rank-sum test unless otherwise specified. Comparisons in Figures 5 (except 5F)
and S6 were Mann–Whitney test by GraphPad Prism for unpaired data or Wilcoxon
matched-pairs signed rank test by GraphPad Prism for paired data. All other statistical
analyses were performed in the R Statistical Computing environment v3.3.1 (http://www.rproject.org).

Author Manuscript

DATA AND SOFTWARE AVAILABILITY
See key resources table. The human sequencing data (WES, RNA-seq, TCR-seq) are
deposited into a controlled-access database managed by Bristol-Myers Squibb. Sequencing
data may be accessed, on approval, by individual investigators upon request (https://
fasttrack.bms.com and christine.horak@bms.com). The online version of the paper will be
updated to include the accession numbers once they are available. Code and additional
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processed data to reproduce key results contained within the manuscript are available at
https://github.com/riazn/bms038_analysis.

Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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HIGHLIGHTS
•

A prospective trial reveals molecular actions of anti-PD-1 therapy

•

Anti-PD-1 therapy induces changes in the mutational burden of tumors

•

Distinct changes in gene expression programs associate with clinical response

•

Shifts in the TCR repertoire occur following immune checkpoint blockade
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Figure 1. Genomic Features and Sculpting of the Tumor Mutational Landscape by
Immunotherapy

Author Manuscript

(A) Baseline genomic characteristics of melanoma tumors from patients treated with
immune checkpoint therapy. An OncoPrint image of WES data for the cohort sorted by
response group (CR/PR, SD, PD). The OncoPrint displays genes recurrently mutated in
melanoma and genes that have been recently associated with response to therapy.
B) Left: Analysis of clonality in pre-therapy samples identifies a trend toward more
subclonal mutations in Ipi-P patients (p = 0.08; Mann–Whitney test; see also Figure S1A).
Right: OS in Ipi-N patients by mutation load (high mutation load defined as >100
mutations).
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(C) Waterfall plot of change in mutation (non-synonymous) and putative neoantigen load
between pre-therapy biopsy and cycle 1, day 29 on-therapy biopsy by response status.
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Figure 2. Changes in Tumor Clonal Composition after Treatment with Nivo Therapy

(A) Changes in CCF of mutations (synonymous and non-synonymous, clonal/subclonal)
from pre- to on-therapy samples. Similar CCFs in both pre- and on-therapy samples
(genomic persistence) in gray; increased CCF or novel in on-therapy samples (genomic
expansion) in pink; decreased CCF/lost in on-therapy samples (genomic contraction) in blue.
(B) Lost mutations indicating genomic contraction were ubiquitous in CR/PR samples, and
significantly more frequent in patients with SD than PD. Persistent mutations were less
common in samples without response and not significantly different between patients with

Cell. Author manuscript; available in PMC 2018 November 02.

Riaz et al.

Page 28

Author Manuscript

SD and PD. Variant gains (genomic expansion) were significantly more frequent in patients
with PD than SD. Data are presented as median and interquartile range (IQR).
(C) Left: Waterfall plot of net change between fraction of mutations representing genomic
contraction and genomic persistence. Right: OS and PFS by genomic contraction and
genomic persistence (p = 0.003; log-rank test and p = 3.34e–4; log-rank test, respectively).
(D) Changes of CCF in representative cases from patients with CR/PR (patient 53), SD
(patient 10) and PD (patient 27). Tree diagrams illustrate the relationships between the
clones. Colored lines and circles denote specific clones.
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Figure 3. Pre-therapy Tumor Gene Expression Analysis
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(A) Hierarchal clustering analysis of DEGs in tumors from pre-therapy biopsies.
(B) Heatmap associations of gene expression signatures in the Ipi-P and Ipi-N cohorts.
C) Analysis of DEGs in tumors with genomic contraction versus those with genomic
persistence (n = 26).
(D) Left: Clustering of the entire cohort of patients (n = 45) by DEGs identified in (C)
clusters patients into two groups in entire cohort and into four groups in combined Hugo et.
al. and Van Allen et. al. cohorts. Right: Long-term OS associates with clustered groups of
patients from the entire cohort and from the combined Hugo et al. and Van Allen et al.
cohorts.
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Figure 4. Changes in Gene Expression Following Nivo Therapy

Author Manuscript

(A) Left: Analysis of ratio of DEGs and selected genes between pre- and on-therapy
samples. Right: Examples of genes that change after initiation of Nivo.
(B) Analysis of changes in gene expression (on-therapy compared with pre-therapy) that are
altered in tumors that respond or do not respond to Nivo.
(C) Graphical illustration of key pathways differentially expressed in (B).
(D) Immune deconvolution of RNA-seq data comparing pre- and on-therapy samples. Data
are presented as median and IQR.
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Figure 5. T-Cell Infiltrate and Repertoire Association with Response to Nivo

Author Manuscript

Due to the reduced number of cases with paired TCR-seq data, patients with CR/PR and SD
were grouped as having “benefit”, and patients with PD were considered to have “no
benefit”.
(A) Change in TIL abundance and activity as measured by multiple methods (DNA-based
TCR-seq, IHC, and RNA-based cytolytic score). Data are presented as median and IQR.
(B) Change in richness and evenness of intratumoral T-cell repertoires. *Two outliers were
removed per Grubbs’ test, alpha = 0.1 (see Methods). Data are presented as median and
IQR.
(C) Median richness and evenness of CDR3s per VJ combinations pre-therapy and ontherapy (see also Figure S6E).
(D) Kernel density plots of CDR3 evenness versus number of unique CDR3s for every
observed VJ pair in selected patients.
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(E) Comparison of on-therapy TIL levels with changes in T-cell repertoire evenness (D90,
defined as the minimum fraction of total unique CDR3 sequences that constitutes 90% of all
sequencing reads).
(F) Fraction of on-therapy TCR repertoire utilizing V-segments associated with CD8 or CD4
T cells. Data are presented as mean ± SEM.
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Figure 6. T Cells Expand in Proportion to Depletion of Neoantigens
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(A) Changes in T-cell population distribution (i.e., evenness) and changes in tumor mutation
clonality by response.
(B) Relationship between the number of predicted neoantigens lost and the number of T-cell
clones expanded on-therapy.
(C) Neoantigen ratios (mutations predicted to generate neoantigens per mutations not
predicted to generate neoantigens) from mutations solely identified in pre-therapy samples
compared with those identified solely in on-therapy samples. Data are presented as mean ±
SEM.
(D) Graphical model depicting changes during anti-PD-1 therapy. (a) Changes in mutations
and neoantigens during therapy. (b) Changes in TCR repertoire depend on exposure to prior
immunotherapy. (c) Changes in immune landscape and checkpoints during therapy.
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